Martin Pauline L, Oneda Satoru, Treacy George
Department of Toxicology and Investigational Pharmacology, Centocor Research and Development Inc., Radnor, PA 19087, USA.
Am J Reprod Immunol. 2007 Aug;58(2):138-49. doi: 10.1111/j.1600-0897.2007.00499.x.
The use of anti-TNF-alpha therapies during pregnancy and lactation on the development of the neonatal immune system has not been fully established. The purpose of this study was to evaluate whether treatment of macaques with an anti-TNF-alpha monoclonal antibody (golimumab) during pregnancy and lactation would result in defects in the developing immune system.
Pregnant macaques were treated with golimumab during pregnancy and lactation. Immune system development was evaluated by histopathology, lymphocyte subset analysis and functional challenging of the infant immune system (humoral immune response to KLH and TTX, and DTH skin reaction).
In utero and postnatal exposure to golimumab had no effect on T and B cell populations in blood and lymphoid tissues and did not impair the ability of the infants to mount an immune response to antigen challenge.
Treatment of pregnant macaques with golimumab throughout pregnancy and lactation did not affect the development and maturation of the immune system in the offspring.
孕期及哺乳期使用抗肿瘤坏死因子-α（TNF-α）疗法对新生儿免疫系统发育的影响尚未完全明确。本研究的目的是评估孕期及哺乳期用抗TNF-α单克隆抗体（戈利木单抗）治疗猕猴是否会导致发育中的免疫系统出现缺陷。
对怀孕猕猴在孕期及哺乳期用戈利木单抗进行治疗。通过组织病理学、淋巴细胞亚群分析以及对婴儿免疫系统的功能激发（对钥孔戚血蓝蛋白和破伤风类毒素的体液免疫反应以及迟发型超敏皮肤反应）来评估免疫系统发育情况。
宫内及出生后接触戈利木单抗对血液及淋巴组织中的T细胞和B细胞群体没有影响，也未损害婴儿对抗抗原激发产生免疫反应的能力。
怀孕猕猴在整个孕期及哺乳期用戈利木单抗治疗不会影响后代免疫系统的发育和成熟。
